Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development.

Animals Colitis Colon / microbiology Dextran Sulfate Disease Models, Animal Dysbiosis / complications Imiquimod / adverse effects Inflammatory Bowel Diseases / etiology Mice Mice, Inbred C57BL Psoriasis / chemically induced
CP: Immunology CX(3)CR(1)(hi) macrophages DSS colitis dysbiosis gut homeostasis gut microbiota imiquimod-induced psoriasis succinate

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
16 08 2022
Historique:
received: 05 11 2021
revised: 30 05 2022
accepted: 19 07 2022
entrez: 17 8 2022
pubmed: 18 8 2022
medline: 20 8 2022
Statut: ppublish

Résumé

Psoriasis has long been associated with inflammatory bowel disease (IBD); however, a causal link is yet to be established. Here, we demonstrate that imiquimod-induced psoriasis (IMQ-pso) in mice disrupts gut homeostasis, characterized by increased proportions of colonic CX

Identifiants

DOI: 10.1016/j.celrep.2022.111191 PMID: 35977500
pubmed: 35977500
pii: S2211-1247(22)01008-7
doi: 10.1016/j.celrep.2022.111191
pii:
doi:

Substances chimiques

Dextran Sulfate 9042-14-2
Imiquimod P1QW714R7M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

111191

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Gabriela Veronica Pinget (GV)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Jian Kai Tan (JK)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Duan Ni (D)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Jemma Taitz (J)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Claire Immediato Daien (CI)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; CHRU Montpellier, University of Montpellier & INSERM U1046, CNRS UMR, PhyMedExp, 9214 Montpellier, France.

Julie Mielle (J)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; CHRU Montpellier, University of Montpellier & INSERM U1046, CNRS UMR, PhyMedExp, 9214 Montpellier, France.

Robert John Moore (RJ)

School of Science, RMIT University, Bundoora, VIC 3083, Australia.

Dragana Stanley (D)

School of Health, Medical and Applied Sciences, Central Queensland University, Kawana, QLD 4701, Australia.

Stephen Simpson (S)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Life and Environmental Sciences, Faculty of Sciences, The University of Sydney, Sydney, NSW 2006, Australia.

Nicholas Jonathan Cole King (NJC)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.

Laurence Macia (L)

The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; School of Medical Sciences, Chronic Diseases Theme, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Sydney Cytometry, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: laurence.macia@sydney.edu.au.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du côlon › Colite › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Système digestif › Tube digestif › Tube digestif inférieur › Gros intestin › Côlon › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Glucides › Polyosides › Glucanes › Dextrane › Sulfate dextran › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Dysbiose › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Aminoquinoléines › Imiquimod › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies inflammatoires intestinales › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Dysbiosis in imiquimod-induced psoriasis...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses papulosquameuses › Psoriasis › Dysbiosis in imiquimod-induced psoriasis...